SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors. In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02.

SNK02有可能成为一流的冷冻保存同种异体NK细胞治疗实体瘤的方法，在给药前不需要淋巴清除，这可能会在未来与免疫检查点抑制剂的联合治疗方案中产生更好的整体协同作用。在这项1期临床试验中，100%完成8个SNK02治疗周期的患者表现出稳定疾病的最佳客观反应。

SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion. SANTA ANA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced an online publication, titled “Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion” at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

SNK02作为单一疗法具有良好的耐受性，尽管缺乏淋巴清除，但似乎对预处理的实体瘤具有一定的临床活性。加利福尼亚州圣安娜，2024年5月23日（环球通讯社）--NKGen Biotech，Inc.（纳斯达克：NKGN）（“NKGen”或“公司”），一家临床阶段生物技术公司，专注于创新性自体，同种异体和CAR-NK自然杀伤（“NK”）细胞治疗剂的开发和商业化，今天在2024年美国临床肿瘤学会（“ASCO”）年会上宣布了一份在线出版物，题为“使用冷冻保存的非基因修饰的具有增强细胞毒性的同种异体自然杀伤细胞（SNK02）对无淋巴结清除的晚期实体瘤患者进行I期研究的中期分析”，该年会将在伊利诺伊州芝加哥的McCormick Place会议中心举行2024年5月31日至6月4日。

This Phase 1 clinical trial is a multi-center, open-label study evaluating the safety and tolerability of SNK02 in participants with pathologically confirmed solid tumors refractory to standard of care therapy. The study drug, SNK02, is a first-in-kind, cryopreserved allogeneic non-genetically modified NK cell product with significant anti-tumor cytotoxicity and over 90% expression of CD16, NKG2D, NKp46, and DNAM-1, that can be consistently produced on a large commercial scale.

这项1期临床试验是一项多中心，开放标签研究，评估了SNK02在经病理证实的标准治疗难治性实体瘤患者中的安全性和耐受性。研究药物SNK02是第一种冷冻保存的同种异体非基因修饰NK细胞产物，具有显着的抗肿瘤细胞毒性和超过90%的CD16，NKG2D，NKp46和DNAM-1表达，可以持续生产大规模商业规模。

.

.